Triple

T5981239
Position Surface form Disambiguated ID Type / Status
Subject Elan Pharmaceuticals E133121 entity
Predicate developed P73 FINISHED
Object bapineuzumab
Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
 E559467 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: bapineuzumab | Statement: [Elan Pharmaceuticals, developed, bapineuzumab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: bapineuzumab
Context triple: [Elan Pharmaceuticals, developed, bapineuzumab]
  • A. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • B. ocrelizumab
    Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
  • C. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • D. Actemra
    Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
  • E. Namenda
    Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: bapineuzumab
Triple: [Elan Pharmaceuticals, developed, bapineuzumab]
Generated description
Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: bapineuzumab
Target entity description: Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
  • A. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • B. ocrelizumab
    Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
  • C. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • D. Actemra
    Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
  • E. Namenda
    Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c0086f45e8819098f73dd16d45ec9d completed March 22, 2026, 3:19 p.m.
NER Named-entity recognition batch_69c04a67c3248190ba35a7121eb49672 completed March 22, 2026, 8 p.m.
NED1 Entity disambiguation (via context triple) batch_69c0e42174a88190b8b40cbc7815911f completed March 23, 2026, 6:56 a.m.
NEDg Description generation batch_69c0f602b79881909a6d971972f760b1 completed March 23, 2026, 8:12 a.m.
NED2 Entity disambiguation (via description) batch_69c0f6a75b908190b35d13b9593cf21f completed March 23, 2026, 8:15 a.m.
Created at: March 22, 2026, 4:04 p.m.